- Healthcare 150
- Posts
- FemTech to $130B, a $2B MedTech Move, and a 65% Drop in Late-Stage VC
FemTech to $130B, a $2B MedTech Move, and a 65% Drop in Late-Stage VC
FemTech targets a $130B valuation and Teleflex executes $2B in strategic carve-outs, while late-stage HealthTech funding drops 65% amid a widening global confidence gap.
Good morning, ! This week we’re diving into FemTech’s evolution from niche to market pillar, a $2B medtech carve-out reshaping strategic focus, the volatile-but-viable state of HealthTech VC, shifting global momentum in medical devices, and a growing confidence gap across life sciences markets.
Want to advertise in Healthcare 150? Check out our self-serve ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
DATA DIVE
FemTech’s Growth Curve Goes Mainstream
This week’s data dive lands on the surging FemTech market, which is scaling from $55.9B in 2024 to $130.8B by 2034, a steady 9.2% CAGR that would make most digital-health subsectors jealous. What was once dismissed as niche is now a structural pillar supported by rising digital health adoption, expanded reimbursement pathways, and long-overdue investment in women’s health. Regionally, North America commands 39% share, but Asia-Pacific is the fastest climber as mobile-first care models reshape access. The market is still anchored in pregnancy, maternal care, and fertility—collectively nearly 79% of activity—but emerging momentum around menopause and chronic-condition tools signals the next frontier. Devices hold the revenue lead at 52%, yet software and services are growing faster as hybrid ecosystems take over.
TREND OF THE WEEK
A Confidence Gap in Global Life Sciences
Life sciences leaders are split on the industry’s 2026 outlook—and the divide is geographic. According to Deloitte, 89% of non-U.S. executives are optimistic about the industry's performance in 2026, compared to just 60% of U.S.-based leaders.
The contrast is stark. Only 1% of non-U.S. respondents expressed pessimism, versus 23% of U.S. leaders. This suggests a confidence gap that could reflect differences in regulatory headwinds, pricing pressure, or innovation pipelines.
Why it matters: U.S. market sentiment may be cooling amid increasing scrutiny on drug pricing, reimbursement uncertainty, and shifting FDA dynamics. Meanwhile, international markets—particularly in Asia and Europe—may be benefiting from policy tailwinds and more favorable market conditions. For investors and strategics, the signal is clear: optimism isn’t evenly distributed, and capital may increasingly follow confidence. (More)
PRESENTED BY RAD INTEL
The AI Infra Layer Powering Fortune 1000 Growth
RAD Intel is already embedded across Fortune 1000 marketing stacks, functioning as the infra layer that verifies customers, cuts waste, and accelerates revenue. The metrics match what M&A teams underwrite: rapid ARR growth, rising enterprise penetration, strong retention, and efficient sales payback.
$60M+ raised. 5,000%+ valuation lift in four years*. 14,000+ investors. Nasdaq ticker $RADI reserved. Leadership has closed $9 Billion+ in M&A deals.
With AI infra acquisitions hitting $55B this year, decision-layer platforms like RAD are commanding premium attention.
HEALTHTECH CORNER
The Diagnosis: Volatile but Viable
HealthTech VC isn’t flatlining—but it does need a second opinion. 2025 started strong, thanks to a Q1 jolt from Europe, which briefly accounted for over 25% of global deal volume. That ended fast: European funding dropped 43% in Q2 and kept falling. Meanwhile, the lifeblood of the rally—late-stage deals—has thinned out. Series C+ rounds are on track to plunge 65% by Q3, down $1.1B from earlier this year. Still, this isn't a crash. With a typical Q4 bounce, the sector could close 2025 at $17.7B—not bad for a post-pandemic cooldown. Just don’t expect 2021-style champagne showers. (More)
TOGETHER WITH FISHER INVESTMENTS
13 Investment Errors You Should Avoid
Successful investing is often less about making the right moves and more about avoiding the wrong ones. With our guide, 13 Retirement Investment Blunders to Avoid, you can learn ways to steer clear of common errors to help get the most from your $1M+ portfolio—and enjoy the retirement you deserve.
DEAL OF THE WEEK
Teleflex’s $2B Carve-Out Sharpens Strategic Focus
Teleflex is offloading non-core assets in a pair of deals totaling $2B, as it doubles down on critical care and cardiovascular devices.
First, private equity firms Montagu and Kohlberg will acquire Teleflex’s OEM unit for $1.5B, spinning it into a standalone global contract developer. The business spans catheter components, surgical fibers, and assemblies for interventions across structural heart, neurovascular, and urology—with seven plants in the U.S., Mexico, and Ireland. Teleflex OEM’s current GM, Greg Stotts, will lead the new entity as CEO.
Second, UK-based Intersurgical is picking up Teleflex’s acute care and interventional urology portfolio for $530M, gaining assets like the UroLift system for BPH and anesthesia/respiratory lines.
Why it matters: This marks a clean break for Teleflex, aligning its portfolio squarely around high-growth cardiovascular segments. With proceeds fueling a $1B share buyback, the move isn’t just about focus—it’s about unlocking value. For PE and strategics, it's another example of how carve-outs are becoming a preferred tool for medtech realignment and platform-building. (More)
REGIONAL FOCUS
North America’s Lead, Asia’s Momentum
North America’s 40% market share shows the region is still the gravitational center of medical device adoption. A mature healthcare system, deep R&D, and industry giants clustered across the U.S. keep innovation on a tight release cycle. Add favorable reimbursement policies and a rapid shift toward home healthcare, and it’s clear why North America continues to dominate. Europe’s 30% slice remains steady, but the real acceleration is in Asia Pacific (24%), where escalating chronic diseases, rising per-capita income, and heavy infrastructure investment from India and China are reshaping demand. As digital health, IoMT, and analytics scale, APAC’s growth trajectory is starting to look less incremental and more inevitable for M&A buyers hunting the next frontier. (More)
"Action is the foundational key to all success."
Pablo Picasso